Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. NOVO
  4. NOVO — Januar 2025

NOVO — Januar 2025

Planlagt Fastgjort Låst Flyttet NOVO
233 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #101

    Analytikere er langt mere positive, end de plejer. 32 danske aktier spås kursstigninger på over 10 pct. i 2025. +42,1% i Novo https://borsen.dk/nyheder/investor/analytikere-sa-meget-skal-danske-aktier-stige?b_source=borsen&b_medium=row_0&b_campaign=news_1

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #102

      Fra Reuters "Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
      By Patrick Wingrove
      Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
      Novo Holdings last month closed a $16.5 billion deal to buy U.S.-based

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #103

        Catalent. The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of its popular weight-loss drug Wegovy.
        Jonathan Levy, the Novo Holdings partner who led the deal, in an interview this week said his firm did not want to overcommit to a revenue target before it had a chance to set out a corporate strategy with Catalent's management.
        "But doubling the size of

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #104

          your business over five years is always a nice barometer to work on, and I think we could do something more here from an enterprise value perspective," Levy told Reuters at the JPMorgan health conference in San Francisco.
          Catalent, which had sales of $4.38 billion in 2024, will hold its next board meeting in February, according to Levy.
          Levy said he expects more drugmakers that currently rely on manufacturers in China and India to look for western service providers with Trump set to return to

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #105

            to the White House on Monday, given his America first focus.
            Catalent and Thermo Fisher Scientific unit Patheon -- two of the largest contract drug manufacturers based in the U.S. -- could be beneficiaries of such moves.
            In addition to his outspoken preference for U.S. manufacturing, Trump has said he will hit China with new tariffs on the first day of his presidency, but Levy did not discuss how that might affect pharmaceuticals.
            Levy said Novo Holdings has a venture vehicle with more than 90

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #106

              biopharmaceutical assets that will be "a tremendous pipeline" for Catalent.
              He also said he was closely watching lawmaker efforts to pass a bill that would restrict U.S. business with certain Chinese biotechnology companies, including contract drug manufacturer WuXi AppTec.
              "Companies like WuXi, for example, they (will) struggle as a result of it," Levy said, "and companies like Catalent will benefit."

              1 Reply Last reply
              0
              • L Offline
                L Offline
                lahn1
                wrote on sidst redigeret af
                #107

                Det er super spændende JKY tak for copy paste

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #108

                  Velbekomme lahn1

                  1 Reply Last reply
                  0
                  • SvingtraderenS Offline
                    SvingtraderenS Offline
                    Svingtraderen
                    wrote on sidst redigeret af
                    #109

                    ****NOVO NORDISK: HØJDOSIS UDGAVE AF SEMGLUTID VISER VÆGTTAB PÅ 20,7 PCT

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #110

                      Guggenheim Securities höjer riktkursen för Novo Nordisk till 798 danska kronor (795), upprepar köp - BN

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #111

                        Tak ST, det burde da være en god nyhed, men markedet havde måske forventet et større vægttab?

                        1 Reply Last reply
                        0
                        • SvingtraderenS Offline
                          SvingtraderenS Offline
                          Svingtraderen
                          wrote on sidst redigeret af
                          #112

                          ja tror folk benhårdt sammenligner med Lilys (bedre nok..)

                          1 Reply Last reply
                          0
                          • SvingtraderenS Offline
                            SvingtraderenS Offline
                            Svingtraderen
                            wrote on sidst redigeret af
                            #113

                            og velbekomme

                            1 Reply Last reply
                            0
                            • C Offline
                              C Offline
                              Craw
                              wrote on sidst redigeret af
                              #114

                              Jeg mener da, at Eli Lillys netop opnåede et vægttab på 20,2%, hvorfor det blev udråbt til bedre end Wegovy. Nu rammer Wegovy så 20,7% i højeste dosis. Men der er igen fokus på Naion øjensygdommen. Det er lidt besynderligt, at det kommer samme dag. Det er som om, enhver god nyhed fra Novo skal neutraliseres af noget andet, også selvom det primært bare er en gentagelse af noget gammelt.

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                BSinvest
                                wrote on sidst redigeret af
                                #115

                                Novo Nordisk viser vægttab på lidt over 20 pct. med højdosisudgave af Semaglutidhttps://proinvestor.com/investornyt/1266478/novo-nordisk-viser-vaegttab-pa-lidt-over-20-pct-med-hojdosisudgave-af-semaglutid

                                1 Reply Last reply
                                0
                                • SvingtraderenS Offline
                                  SvingtraderenS Offline
                                  Svingtraderen
                                  wrote on sidst redigeret af
                                  #116

                                  ****NOVOS OZEMPIC OG WEGOVY INKLUDERET I MEDICARE-PRISFORHANDLINGER I USA

                                  1 Reply Last reply
                                  0
                                  • SvingtraderenS Offline
                                    SvingtraderenS Offline
                                    Svingtraderen
                                    wrote on sidst redigeret af
                                    #117

                                    enig @craw - intet er åbenbart godt nok pt

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      Jazzz
                                      wrote on sidst redigeret af
                                      #118

                                      Vi må væbne os med tålmodighed og lade omsætning og profit tale når det nu kommer i de kommende år
                                      . Novo er ihvertfald ikke hypet mere..

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #119

                                        33% af deltagerne opnåede vægttab på +25% Fra Børsen “Vi er meget glade for at kunne påvise et vægttab på 20,7 pct. og for at se, at 33 pct. af patienterne opnåede mere end 25 pct. vægttab med semaglutid 7,2 milligram, med en sikkerheds- og tolerabilitetsprofil profil, der kan sammenlignes med semaglutid 2,4 milligram,” siger Martin Holst Lange, koncerndirektør med ansvar for udvikling hos Novo Nordisk. "

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          JKY_VH
                                          wrote on sidst redigeret af
                                          #120

                                          det er da alligevel noget

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper